Public health officials hope that once the vaccine becomes available, more and more people will have to be vaccinated to turn the tide of the coronovirus epidemic – even those who have already recovered from Kovid-19.
And while it is not yet known how the immune system of Kovid-19 survivors respond to a vaccine – “long-lived,” especially among coronoviruses, whose symptoms occur weeks and months after their diagnosis Are – There is a possibility of little risk in the film segment.
Professor of Medicine and Director of Infectious Diseases Division, Director of Johns Hopkins University School of Medicine, Drs. David Thomas said, “The usual vaccination is to get the vaccine, even if you were previously infected.” “There are some granular questions that we don’t yet have an answer to, but what we know now is the right call to get the vaccine.”
Kovid-19 recombination is considered rare, but if the level of natural antibodies decreases over time, it may be possible for an individual to become infected more than once. Doctors and infectious disease experts agree that most people should get vaccinated, even if they have natural protective immunity. In most survivors, a vaccine can also increase immunity from early infections.
This is an example. Healthy adults over 50 years of age are still advised to get herpes vaccine, even if they have had chickenpox or herpes before.
“I did this because I wanted extra immunity to protect me against a ringworm later in life,” Thomas said of his recent decision to get herpes vaccine. “Although I was already infected and had a certain amount of immunity, I doubled down on that and opted to get the vaccine to make me safe.”
The Food and Drug Administration is reviewing data from two vaccine candidates created by Pfizer and Modern, and an independent advisory committee to the Centers for Disease Control and Prevention voted Tuesday to approve the recommendations, which Must be in the first line to take shots. The recommendations will go to the director of the CDC for official signoff. The planned rollout has widespread implications for how the epidemic would rebel, but it also raises questions about how about 14 million who have already confirmed cases of Kovid-19 in the US were affected. Will be
Vaccine trials established by Pfizer and Modern included participants from racially and ethnically diverse backgrounds, but did not focus on those who had previously been ill with Kovid-19.
Detailed views of this type are part of the vaccine approval process, and Thomas said that Pfizer and Modern would be expected to provide data about a number of outstanding questions even after the FDA grants the Emergency Use Authority.
“Usually after something is approved, the FDA will say that we are approving you, but you have to do all these things within a certain time frame and answer all these questions by a certain date or you will lose approval. ” “Companies are then required to do all these things, but in the meantime, you don’t catch everything.”
Some conditions are likely to include queries specific to those who have Kovid-19, as well as all security data.
So far, there is no evidence that a vaccine would be unsafe for Kovid-19 survivors, but said Dr. Sarah Fortune, chair of immunology and infectious diseases at Harvard TH School of Public Health.
“There have not been any serious adverse events that I think will be a major issue, but I think that has to be analyzed,” she said. “The first question is about safety, but then the second question is: are there any additional benefits?”
Although Pfizer and the Modern Vaccine Trial did not recruit volunteers who were symptomatic or who were already infected, it is believed that up to 10 percent of the participants in the trial had the virus, Chief Science Dr. Monsey Saloui said. Advisor for Operation Tana Pace, an $ 18 billion initiative to support the Trump administration’s development of the coronovirus vaccine. He said that those people were either asymptomatic or had mild symptoms that they had become reluctant.
“We know vaccines are safe in these populations,” Saloi said Wednesday in a news briefing about Operation War Speed. He said more data is needed on how the vaccine works in people who had symptoms and were ill with Kovid-19.
Another big unknown is how Kovid-19 can respond to “long-lived” Michael Bates, an immunologist and professor of microbiology at the University of Pennsylvania’s Perelman School of Medicine.
It is not known how many people suffer from long-term symptoms from Kovid-19, but a CDC study published in July found that 35 percent of adults who were symptomatic, but never ill, did not require hospitalization. Thi, they did not return to their normal health. Three to three weeks after his diagnosis.
Part of the challenge of assessing how those patients may be affected by the vaccine is that much is still unknown about why their symptoms persist.
“We don’t really understand why these individuals suffer in this way, so my concern comes from the fact that we don’t know the cause of these long haul conditions,” Bates said.
Thomas said that without a clear understanding of why symptoms are apparent in some patients, it is difficult to know whether the immune response from the vaccine would be beneficial or harmful.
Thomas said, “People who have chronic inflammatory conditions from Kovid can fall into a category where you don’t suddenly want them to boost the immune system.” “But it is possible that it might make them better, also how little we understand it.”
Bates said the long haul may require an in-person evaluation so doctors can evaluate potential risks and benefits. He added that those patients would also need to be monitored and evaluated over time.
“It can be a special group with a case-by-case decision,” Bates said. “We don’t really understand the long run situation, so trying to predict how a vaccine would perform here is difficult.”